Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TransMedics Group, Inc. - Common Stock (NQ: TMDX )

63.06 +1.36 (+2.21%)
Streaming Delayed Price Updated: 11:39 AM EST, Dec 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about TransMedics Group, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Looking Into TransMedics Gr's Recent Short Interest
Via Benzinga
$100 Invested In TransMedics Gr 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Is TransMedics Stock a Buy Before 2025?
Via The Motley Fool
Beyond The Numbers: 13 Analysts Discuss TransMedics Gr Stock
Via Benzinga
2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid
Via The Motley Fool
$1000 Invested In TransMedics Gr 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Down Over 60%, Is TransMedics Stock a Buy on the Dip?
Via The Motley Fool
Why Transmedics Group Stock Plummeted 21% This Week
Via The Motley Fool
Why TransMedics Stock Plummeted Today
Via The Motley Fool
Behind the Scenes of TransMedics Gr's Latest Options Trends
Via Benzinga
3 Cheap Stocks to Buy Now
Three stocks poised for upside, both near-term and long-term. 
Via The Motley Fool
TransMedics Ushers In New CFO, Tightens 2024 Revenue Goals
TransMedics Group appoints new CFO, Gerardo Hernandez, and adjusts financial outlook for 2024. 
Via Benzinga
Zscaler, TransMedics Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
1 Top Growth Stock Down 56% to Buy After Its Recent Pullback
This growth stock has been on my watchlist for a while and might soon be included in my portfolio. 
Via The Motley Fool
Looking Into TransMedics Gr's Recent Short Interest
Via Benzinga
Navigating 11 Analyst Ratings For TransMedics Gr
Via Benzinga
This Is What Whales Are Betting On TransMedics Gr
Via Benzinga
2 Hypergrowth Stocks That Are Screaming Buys in November
Via The Motley Fool
This HCA Healthcare Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Jim Cramer Likes Devon Energy, But Calls Another Stock 'Far Superior'
Amphenol (APH) is a terrific stock, reporting better-than-expected earnings, while Cramer prefers CTRA over DVN and doesn't see potential in TMDX. 
Via Benzinga
Is TransMedics Group Stock a Buy?
This organ transplant specialist is down, but still has plenty of signs of life. 
Via The Motley Fool
Down 52%, Is TransMedics Stock a Buy on the Dip?
Sales growth is tapering off for this provider of delivery services for transplant organs. 
Via The Motley Fool
Why TransMedics Stock Plunged in October
The organ transplant specialist posted disappointing results in its third-quarter report. 
Via The Motley Fool
1 Top Growth Stock Down 50% to Buy After Its Recent Pullback
TransMedics quickly became the leader in liver, heart, and lung transplants, but its third-quarter earnings left the market worried. Here's why I believe its pullback in share price is an opportunity. 
Via The Motley Fool
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
3 Stocks Well Below 52-Week Highs With Strong Growth Projections
These three stocks are trading deeply below their 52-week highs, and analyst project them to see big increases in earnings and revenue over coming years. 
Via MarketBeat
Topics Immigration
Exposures Immigration
Gold Gains 1%; Phillips 66 Shares Fall After Q3 Results
Via Benzinga
Organ Transplant MedTech TransMedics Q3 Performance Disappoints, Analyst Outlines Investor Worries
TransMedics Group shares fall as Q3 EPS misses estimates; revenue rises 64% but falls short of consensus. Analysts cut price targets, citing weaker transplant volumes. 
Via Benzinga
Nasdaq Surges Over 100 Points; Pfizer Earnings Top Views
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.